ACHN Volume Alert - ACHN 12.85 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 11:45 AM

ACHN Volume Alert - ACHN 12.85 Achillion Pharmaceuticals $ACHN Hit a high of 13.38 Currently 11:15 Last price 12.85 unch unch With a day low of 12.22 and a current volume of 7,590,134.

ACHN Achillion Pharmaceuticals Recent Headline News

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - 32 mins ago
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - 42 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - 1 hr 37 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 2 hrs 7 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - 2 hrs 14 mins ago
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 15.84 (+0.98), AMD: 2.73 (-0.03), ACHN: 12.73 (-0.12), CLDX: 14.72 (-0.09), ILMN: 187.87 (-0.40)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - 2 hrs 39 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 16.09 (-0.31), ACHN: 12.73 (-0.12), ILMN: 187.87 (-0.40), AFFX: 9.41 (-0.01)

Most active Nasdaq-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
ACHN: 12.73 (-0.12), DNDN: 0.18 (unch), CMCSK: 51.83 (-1.00), ARCP: 8.63 (+0.13), MSFT: 48.86 (-0.03), INTC: 33.44 (+0.18), CMCSA: 52.00 (-0.95), AAPL: 108.85 (+0.02), CSCO: 25.19 (+0.04)

Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.08 (-0.05), PCMI: 8.60 (-0.20), ACHN: 12.73 (-0.12), TGTX: 13.00 (+0.45), AGIO: 84.61 (+2.83), LIOX: 5.31 (-0.23), PLNR: 7.14 (-0.54)

Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.70 (-0.19), JRJC: 7.74 (+1.30), NAVB: 1.00 (-0.03), SANW: 3.60 (-0.04), PLPM: 1.70 (+0.03), RYN: 26.68 (-2.14), INFU: 2.85 (-0.12), LIOX: 5.31 (-0.23), DY: 27.66 (-0.31), MTZ: 24.21 (-0.72), CGIX: 6.49 (-0.19), MUX: 1.32 (+0.09), OREX: 5.08 (-0.05), URRE: 2.43 (-0.13), ACHN: 12.73 (-0.12), REN: 2.60 (-0.30), MPO: 3.14 (-0.07), AKBA: 9.71 (+0.72), TRX: 1.09 (+0.05), PLNR: 7.14 (-0.54)

Achillion up on HCV data
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:30AM CST

ACHN: 12.73 (-0.12)

Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31)

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST

PT: 1.76 (+0.12), GPRO: 75.40 (-0.35), OREX: 5.08 (-0.05), GOGO: 17.81 (-0.59), JRJC: 7.74 (+1.30), UEC: 1.84 (-0.06), ACHN: 12.73 (-0.12), ARQL: 1.17 (unch), CMCM: 19.17 (-1.39), IBIO: 1.17 (-0.06), DF: 16.09 (-0.31)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"

Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 12.73 (-0.12)

Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.73 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Divorce Expertise: Obenhaus Adds CDFA Credential

Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...

Motor Sensor Market to Exceed $5B by 2035 Surge

Motor Sensor Market: Facing a New Era of Growth Buckle up, because this motor sensor market is gearing up for one heck of a ride. We're talking a clunky, gritty transition where the market's supposed to rev up to $5.47 billion by 2035, shooting from $3.21 billion in 2026. If you are crunching those numbers like a true market dog, that's a decent CAGR of 6.1%. But what's...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Gemmy's Orchestra of Lights Op. 2 Unveils New Show

Jazzing Up the Holidays with Gemmy's Latest Innovation Just when you thought holiday displays couldn't get more extravagant, along comes Gemmy with its latest wonder—the Orchestra of Lights™ Op. 2. Exclusively hitting Lowe's shelves, this isn't your average set of twinkling bulbs. It's an all-out sensory assault, mixing tunes straight out of yuletide hit lists with...

COhatch Preps for High-Stakes Ohio Pitch Contest

Ohio Startups Gear Up for Another Fierce Faceoff You wouldn't find me betting against a hungry entrepreneur, especially with $25,000 on the line. That's the prize dangling at this year's Dublin Pitch Competition, hosted by COhatch and the City of Dublin. If there's one thing I'm certain of, it's that Ohio will see some real contenders stepping up on October 15....

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

WellBe Taps New Tech Chief to Elevate Home Care

In a move that's got the healthcare world buzzing, WellBe Senior Medical just brought in a heavyweight to steer its digital ship. They've appointed Jeffrey Brown as their new Chief Digital & Information Officer. What's shaking? Brown's stepping into the ring to tackle the age-old healthcare dilemma: making tech work smarter, not harder, especially at home. From High-Tech...

Stephen A. Smith Calls for Corporate Support of HBCUs

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...

Lowcountry Kids to Get Free Helmets at Safety Events

Helmets for Kids Initiative Gets Rolling Now, here's a story that's more about community care than cash flow, but hey, sometimes even a grizzled trader like me can nod in appreciation. Christmas Injury Lawyers are putting their money where their mouth is, with the Helmets for Kids initiative staged at two key events in the Lowcountry area. Yep, that's right—the legal...

Reel Drops: Eightpoint's New Social Drama App Explored

Mobile Drama: A Quick Escape with Reel Drops In this fast-moving world, where time feels as elusive as a daydream, Eightpoint is shaking up mobile entertainment with its brand-new app, Reel Drops. Based out of George Town, Cayman Islands, this app aims to give viewers a shot at swift, captivating storytelling without the marathon commitment of a binge-watch session. A New...